News
MEDP
406.51
-4.11%
-17.42
Assessing Medpace Holdings (MEDP) Valuation After Recent Share Price Pullback
Simply Wall St · 11h ago
4 Analysts Have This To Say About Medpace Hldgs
Benzinga · 21h ago
Medpace Holdings Is Maintained at Underweight by Barclays
Dow Jones · 1d ago
Medpace Holdings Price Target Cut to $500.00/Share From $525.00 by Barclays
Dow Jones · 1d ago
Barclays Maintains Underweight on Medpace Hldgs, Lowers Price Target to $500
Benzinga · 1d ago
Medpace price target lowered to $539 from $555 at Truist
TipRanks · 1d ago
Medpace Holdings Price Target Cut to $539.00/Share From $555.00 by Truist Securities
Dow Jones · 1d ago
Medpace Holdings Is Maintained at Hold by Truist Securities
Dow Jones · 1d ago
Truist Securities Maintains Hold on Medpace Hldgs, Lowers Price Target to $539
Benzinga · 1d ago
Walmart To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 1d ago
MEDPACE HOLDINGS INC <MEDP.O>: DEUTSCHE BANK CUTS TARGET PRICE TO $480 FROM $600
Reuters · 1d ago
MEDPACE HOLDINGS INC <MEDP.O>: TRUIST SECURITIES CUTS TARGET PRICE TO $539 FROM $555
Reuters · 1d ago
Medpace Holdings Is Maintained at Market Perform by Leerink Partners
Dow Jones · 1d ago
Medpace Holdings Price Target Cut to $485.00/Share From $575.00 by Leerink Partners
Dow Jones · 1d ago
MEDPACE HOLDINGS INC <MEDP.O>: MIZUHO CUTS TARGET PRICE TO $582 FROM $660
Reuters · 1d ago
Leerink Partners Maintains Market Perform on Medpace Hldgs, Lowers Price Target to $485
Benzinga · 1d ago
MEDPACE HOLDINGS INC <MEDP.O>: BMO CUTS TARGET PRICE TO $460 FROM $600
Reuters · 1d ago
MEDPACE HOLDINGS INC <MEDP.O>: BARCLAYS CUTS TARGET PRICE TO $500 FROM $525
Reuters · 1d ago
Zelluna Selects Medpace to Run First Clinical Trial for ZIMA-101
Reuters · 1d ago
Medpace Holdings (MEDP) Margin Compression Tests Bullish Earnings Growth Narrative In FY 2025
Simply Wall St · 1d ago
More
Webull provides a variety of real-time MEDP stock news. You can receive the latest news about Medpace Holdings through multiple platforms. This information may help you make smarter investment decisions.
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.